Company Profiles

driven by the PitchBook Platform

Carmell Therapeutics

Carmell Therapeutics
2007 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B1 LATEST DEAL TYPE
$2.33M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of plasma-based bioactive materials (PBMs) designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures. The company's proprietary process binds and cross-links lyophilized plasma into solid and semi-solid plasma-based materials and these PBMs contain highly concentrated natural regenerative factors that promote healing in various clinical settings, reduce infections, and, as a result, lower healthcare costs.

Formerly Known As
CarMell
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 2403 Sidney Street
  • Suite 300
  • Pittsburgh, PA 15203
  • United States

+1 (412) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Carmell Therapeutics’s full profile, request a free trial.

Carmell Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B1) 10-Jan-2018 $2.33M 000.00 000.00 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series B) 30-Jun-2017 00.00 00.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series A1) 11-Jun-2014 00.00 000 000 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series A) 22-Nov-2011 00.00 00.00 00.00 Completed Pre-Clinical Trials
3. Grant 01-Jun-2010 00.000 Completed Product Development
2. Grant 01-Jun-2008 $160K Completed Startup
1. Grant 01-Jun-2007 $180K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Carmell Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 21,064,711 $0.001000 7% $0.22 $0.22 1x $0.22 34.8%
To view this company’s complete Cap Table, request access »

Carmell Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Keiretsu Capital Venture Capital Minority 000 0000 000000 0
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
Ariel Southeast Angel Partners Angel Group Minority 000 0000 000000 0
BlueTree Allied Angels Venture Capital Minority 000 0000 000000 0
Harbor Light Capital Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Carmell Therapeutics Executive Team (9)

Name Title Board
Seat
Contact
Info
Randolph Hubbell Chief Executive Officer, President & Chairman
Donna Godward Chief Quality Officer
Lee Weiss Ph.D Co-Founder and Director
James Burgess MD Co-Founder
Janet Vargo Ph.D Vice President of Clinical Sciences

2 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

Carmell Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
David Anderson Carmell Therapeutics Board Member 000 0000
James Jordan Pittsburgh Life Sciences Greenhouse Board Member 000 0000
Lee Weiss Ph.D Carmell Therapeutics Co-Founder and Director 000 0000
Randolph Hubbell Carmell Therapeutics Chief Executive Officer, President & Chairman 000 0000
Richard Upton Harbor Light Capital Partners Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »